Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
The incidence and prevalence of metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) are rising globally. MetS and T2DM are associated with significant morbidity and mortality, which is partly related to liver and cardiovascular disease. Insulin resistance is central to MetS and T2DM pathophysiology, and drives ectopic fat deposition in the liver, also known as metabolic dysfunction-associated steatotic liver disease (MASLD). MetS and T2DM are not only risk factors for developing MASLD but are also independently associated with disease progression to steatohepatitis, cirrhosis, and hepatocellular carcinoma.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta Source Type: research
More News: Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Cirrhosis | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Hepatocellular Carcinoma | Insulin | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Urology & Nephrology